Preliminary efficacy with daraxonrasib demonstrated in RAS-mutant NSCLC

Daraxonrasib, a drug aimed at the broader RAS oncogene family, showed preliminary efficacy in patients with RAS-mutant non-small cell lung cancer. RAS proteins were long regarded as undruggable, so a clinical signal in this group matters in itself. This is, however, an editorial highlight in Nature Reviews Clinical Oncology, with no response rate, patient number or trial phase reported — until the full data appear, the result cannot be weighed against current treatment.